Aspirin is inexpensive, widely available, and supported by randomized evidence, but its bleeding risk limits universal use
Injectable (Subcutaneous) GHK-Cu Subcutaneous injection delivers GHK-Cu systemically
7%), [2] which is reassuring at the scale studied, but Phase 2 trials are not powered to detect uncommon serious risks, and their durations are too short to characterize long-term effects on body composition (including lean mass), bone, or rare adverse events
Synthesis: The aggregate evidence suggests that silymarin likely reduces liver enzymes (ALT, AST, GGT) and may improve lipid profiles and liver fat in people with MASLD
And neither does Williams
These changes are relatively minor but significant enough to merit attention, especially for at-risk populations